24/7 Patient Assistance: 760-405-8205

Roman P. Soler, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pleural Mesothelioma Testicular Mesothelioma

specialties & services

  • Bio & Insurance Information

    Dr. Soler started his medical career in his native town Barcelona, graduating from the Universidad Autonoma medical school in 1977. Dr. Roman Soler also completed residency at the same university. For his fellowship Dr. Roman Soler moved to the United States to attend the courses of the University MD Anderson Cancer Center. Currently acting as the chairman of the department of oncology at the Montefiore Medical Center, Dr. Soler specializes and focuses on the treatment of mesothelioma. With a vast career, spanning two continents, Dr. Roman Soler received several awards and had many articles and works published, mainly regarding treatment methods for mesothelioma.

  • Education & Training


    Universidad Autonoma - 1977

    Medical School


    Universidad Autonoma



    University MD Anderson Cancer Center


  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Burke Rehabilitation Hospital

    Languages: English/Spanish

    (914) 597-2500

    785 Mamaroneck Ave

    White Plains, New York 10605

    Read More

    Montefiore Medical Center

    Languages: English/Spanish

    (718) 405-8505

    1695 Eastchester Rd

    Bronx, New York 10461

    Read More

    SBH Health System

    Languages: English/Spanish

    (718) 960-9000

    4422 Third Ave

    Bronx, New York 10457

    Read More
  • Publications & Memberships

    Dr. Roman P. Soler has contributed to 3 publications.

    Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib

    Ling YH1, Li T, Perez-Soler R, Haigentz M Jr.

    See more >>

    Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK

    Yi-He Ling, Ruoping Lin, Roman Perez-Soler, Mol. Pharmacol., 74 (2008)

    See more >>

    Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene

    Li T1, Ling YH, Perez-Soler R.

    See more >>